FDA Accepts Lonvo-z BLA for Priority Review

Evidence Company release · PDUFA March 10, 2027 · Discovery September 8, 2026 · Importance 5/5 · Direction Positive Summary FDA accepted Intellia Therapeutics’ biologics license application for lonvoguran ziclumeran, or lonvo-z, granted Priority Review and set a March 10, 2027 target action date. FDA…